proton pump inhibitors (PPIs) and hearing loss

FREE subscriptions for doctors and students... click here
You have 3 more open access pages.

Since the introduction of omeprazole in 1989, proton pump inhibitors (PPIs) have steadily become the mainstay in treatment of acid-related disorders (1)

  • Pavaci et al undertook an analysis of the audiological characteristics and comorbidity in patients with chronic tinnitus and found that:
    • proton pump inhibitors and levothyroxine showed a statistically significant correlation with the presence of chronic tinnitus (2)

  • Yee et al undertook a study aimed to investigate the association between proton pump inhibitor (PPI) use and risk of sensorineural hearing loss (SNHL) or tinnitus in patients with type 2 diabetes using hospital- and population-based data
    • (n=1,379) found proton pump inhibitor (PPI) use was associated with increased risk of sensorineural hearing loss (SNHL) or tinnitus (OR: 1.61, 95% CI: 1.30-1.99) with higher risk for current or recent use of PPI and high average daily dose


Last edited 03/2022 and last reviewed 03/2022